Thomas Garner - 06 Mar 2026 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role: EVP, Chief Commercial Officer
Issuer symbol: ACAD
Report date: 06 Mar 2026
Net transaction value: $0
Form type: 4
Accepted by SEC: 10 Mar 2026, 18:00:13 UTC
Previous filing: 10 Dec 2024
SEC filing: View on sec.gov
Reporting owner signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact

Key filing fact

Thomas Garner filed Form 4 for ACADIA PHARMACEUTICALS INC (ACAD) on 10 Mar 2026.

Key facts

This page summarizes Thomas Garner's Form 4 filing for ACADIA PHARMACEUTICALS INC (ACAD).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 10 Mar 2026, 18:00.

Change

Previous filing in this sequence was filed on 10 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

CIK 0001996325 Primary reporting owner

Garner Thomas

Relationship: EVP, Chief Commercial Officer
Address: C/O ACADIA PHARMACEUTICALS, INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO
Signature: /s/ Jennifer J. Rhodes, Attorney-in-Fact
Signature date: 10 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ACAD transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +97,947
Change %
Price: $0.000000^*
Shares after: 97,947
Date: 06 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 97,947
Exercise price: $22.16
Footnotes: F1

ACAD transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +28,493
Change %
Price: $0.000000^*
Shares after: 28,493
Date: 06 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 28,493
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.

Footnote F3

The restricted stock units vest in four equal annual installments beginning March 6, 2027.